PT - JOURNAL ARTICLE AU - Abbasi, Nooshin AU - Tremblay, Christina AU - Rajimehr, Reza AU - Yu, Eric AU - Markello, Ross D AU - Shafiei, Golia AU - Khatibi, Nina AU - The ENIGMA-Parkinson’s study AU - Jahanshad, Neda AU - Thompson, Paul M. AU - Gan-Or, Ziv AU - Misic, Bratislav AU - Dagher, Alain TI - Neuroanatomical correlates of polygenic risk for Parkinson’s Disease AID - 10.1101/2022.01.17.22269262 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.17.22269262 4099 - http://medrxiv.org/content/early/2022/11/28/2022.01.17.22269262.short 4100 - http://medrxiv.org/content/early/2022/11/28/2022.01.17.22269262.full AB - Parkinson ‘s Disease (PD) is heritable, however how genetic risk confers vulnerability remains mostly unknown. Here we use genetic and neuroimaging measures from 20,000 healthy adults from the UK Biobank to show that PD polygenic risk score (PRS) is associated with cortical thinning in a pattern that resembles cortical atrophy seen in PD. Conversely, PD PRS is associated with a global increase in cortical surface area. We also show that the genetically determined cortical thinning profile overlaps with the expression of genes associated with synaptic signaling, is dependent on anatomical connectivity and on regional expression of the most significant PD risk genes. Despite identical PRS distributions in males and females, only males show the associated brain features, possibly explaining the sex disparity in PD. We discuss potential mechanisms linking genetic risk to cortical thickness and surface area, and suggest that the divergent effects may reflect separate routes of genetic vulnerability.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grants from the Canadian Institutes of Health Research the Michael J Fox Foundation for Parkinson's Research the Alzheimer's Association the Weston Brain Institute and the Healthy Brains for Healthy Lives (HBHL) initiative of McGill University. NA received a scholarship from the Montreal Neurological Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee/IRB of the McGill University Health Centre gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ukbiobank.ac.uk/ https://www.ppmi-info.org/ https://alleninstitute.org/